Search Results for “Eli Lilly” – media

Well-known products of foreign companies such as AZ, Eli Lilly, and Sanofi were disqualified

On November 14, the Shanxi Provincial Drug and Equipment Centralized Bidding and Procurement Center issued the “Notice on the Adjustment and Disposal of the Price of the Centralized Procurement of Amoxicillin and Other Drugs in the Guangdong Alliance” (hereinafter referred to as the “Notice”). It is worth noting that there are still 11 manufacturers and 20 specifications that refuse to reduce prices for rectification, including well-known pharmaceutical companies, including AstraZeneca, Sanofi, Eli Lilly and other foreign pharmaceutical companies, and their products include well-known brand drugs such as Plavix (clopidogrel bisulfate tablets), Iressa (gefitinib tablets), and Alimta (pemetrexed disodium for injection). The “Notice” emphasizes that the relevant drugs that refuse to accept the price rectification requirements will be disqualified from being selected and the selected price will be disqualified, and will be transferred to the alternative catalog. The platform will increase price risk warnings, and the task volume of the centralized ...
- Source: drugdu
- 39
- November 21, 2024
CIIE Observation | Eli Lilly’s Two “Focuses”

Today, the seventh CIIE opened grandly in Shanghai. Every year, the CIIE is an excellent opportunity for global pharmaceutical companies to showcase their latest research and development results and expand international markets, and it is also a core window for insight into Chinese market opportunities. This year will be no exception. So, let’s take a look at Eli Lilly, a pharmaceutical company with nearly 150 years of history, and its latest thinking. As an all-around warrior, this year Eli Lilly focused on displaying its latest progress in key global disease areas such as diabetes, obesity, Alzheimer’s disease and anti-tumor. In the big and comprehensive layout, Eli Lilly also revealed its two major focuses of development in China: diabetes and obesity, and Alzheimer’s disease. At this CIIE, Eli Lilly focused on displaying tirpotide. This is not surprising. As Eli Lilly’s flagship product, tirpotide is one of the most competitive GLP-1 drugs ...
- Source: drugdu
- 63
- November 7, 2024
AI+drug target discovery | Insitro and Eli Lilly reach strategic agreement to jointly promote new therapies for metabolic diseases

Zhiyao Bang October 23, 2024 09:01 Shanghai On October 9, 2024, insitro, a new drug development company that supports machine learning, announced the signing of three strategic agreements with Eli Lilly, focusing on developing potential new drugs for the treatment of metabolic diseases, including metabolic dysfunction associated fatty liver (MASLD), based on the targets identified by insitro using the company’s AI based platform.Metabolic diseases, including MASLD, affect millions of people worldwide, but effective treatment options are still limited. The current treatment mainly treats the symptoms rather than the root cause. This collaboration aims to combine Insitro’s machine learning platform with Lilly’s expertise in cutting-edge drug delivery and metabolic disease biology to change existing models. According to the first two agreements, Insitro can choose to license Lilly’s proprietary, clinically advanced ternary N-acetylglucosamine (GalNAc) delivery technology, which will be combined with two different small interfering RNA (siRNA) molecules discovered and developed by ...
- Source: drugdu
- 75
- October 24, 2024
Up to 1 billion US dollars! An RNA pharmaceutical company has reached a cooperation agreement with Eli Lilly

On September 4, 2024, HAYA Therapeutics, a pioneering biotechnology company that uses precise RNA guidance to regulate genome targeting therapy for chronic diseases, announced the signing of a multi-year cooperation agreement with Eli Lilly. Both parties will utilize HAYA’s advanced RNA guided regulatory genome platform to support preclinical drug discovery for obesity and related metabolic diseases. The partner will identify multiple RNA targets derived from the regulatory genome to treat these chronic diseases. According to the terms of the cooperation agreement, HAYA will receive a down payment, including equity investment, and is eligible to receive up to $1 billion in preclinical, clinical, and commercial milestone payments, as well as royalties for product sales. HAYA’s proprietary regulatory genome discovery platform can identify long non coding RNA (lncRNA) targets specific to tissues, diseases, and cells, and develop treatment methods targeting RNA, which may have better efficacy and lower toxicity compared to current ...
- Source: drugdu
- 61
- September 9, 2024
Will Novo Nordisk’s Wegovy follow up with the price reduction of over 50% for Eli Lilly’s Zepbound?

MU Biotech Circle Recently, Eli Lilly announced plans to directly sell single dose vials of its weight loss drug Zepbound (tirzepatide) to consumers. The new prices for 2.5mg and 5.0mg doses are $99.75/vial and $137.25/vial, respectively, with corresponding monthly costs of $399 and $549, respectively, with a price reduction of over 50%. Novo Nordisk may adopt a similar strategy towards its Wegovy, with specific details to be revealed by its CEO during a Senate Health Committee hearing on September 24th. Analysts have responded positively to Eli Lilly’s move to lower Zepbound prices and offer the drug through its new self funded pharmacy component on its direct to consumer platform LillyDirect (launched in January this year). Joon Lee, an analyst at Truist Securities, believes that given the high demand for patients willing to purchase at their own expense, there is no reason why other GLP-1 manufacturers should not adopt similar strategies. ...
- Source: drugdu
- 76
- September 4, 2024
Eli Lilly’s Zepbound to be issued in single-dose vials for self-payers

Eli Lilly and Company has announced the availability of Zepbound (tirzepatide) in 2.5mg and 5mg single-dose vials for self-pay for adults with obesity. The move significantly expands the supply of Zepbound in response to high demand and offers a more affordable option for those who self-pay. The vials are priced a minimum of 50% lower than the list price of other incretin medicines for obesity. Lilly has introduced a new self-pay pharmacy component within LillyDirect, enabling patients with a valid prescription to purchase Zepbound directly. The initiative ensures the authenticity of the medicine and safeguards patients from counterfeit products. Lilly also announced its commitment to ensuring that Zepbound is used appropriately and not for cosmetic weight loss, implementing a multi-step verification process for dispensing. The 2.5mg Zepbound vial costs $399 for a four-week supply while the 5mg dose costs $549 – both representing significant savings compared to other treatments. The ...
- Source: drugdu
- 59
- August 29, 2024
Eli Lilly doubles down on Oblique partnership for antibody generation

Eli Lilly is strengthening its ties with Oblique Therapeutics, as the two companies announced an expansion to their collaboration agreement to include a second “high-value target”. Building on the existing agreement from November 2023, Eli Lilly will continue to use Oblique’s AbiProt platform to discover antibodies. Specifically, Sweden-based Oblique will partner with Lilly Catalyze360-ExploR&D, an arm of the company that offers clinical development capabilities for partnered biotechs and drug developers, as per a 22 August press release. The financial terms of the expanded deal were not disclosed, and neither was the target of its application. Oblique did state that if treatments are developed successfully, the partnership will “generate milestones and royalties”. Abiprot identifies therapeutic antibodies that can be programmed to have a specific pharmacological function. Oblique states its technology can help develop effective medicines against difficult-to-drug target proteins. The biotech’s platform uses microfluidics and proteases as molecular probes and provides ...
- Source: drugdu
- 83
- August 27, 2024
Eli Lilly Drug Reduces Risk of Diabetes Onset, Building Case for Broader Use of the Therapy

In a Phase 3 study, Eli Lilly’s tirzepatide led to a 94% reduction in the risk that obese or overweight prediabetes patients progress to type 2 diabetes. Lilly was already planning to expand use of the blockbuster metabolic disorders drug to sleep apnea and heart failure. By Frank Vinluan The longest clinical trial to date for a blockbuster Eli Lilly metabolic disorder drug now has data showing the treatment delayed progression to type 2 diabetes in patients who are obese or overweight, results that continue to build the case of broader health benefits for the therapy. The preliminary results announced Tuesday come from a clinical trial designed to test once-weekly injections of tirzepatide in prediabetes participants. In addition to being overweight or obese, participants also had at least one weight-related complication, excluding diabetes. The main goal of the placebo-controlled study is assessing tirzepatide’s effect on weight. At the highest of three ...
- Source: drugdu
- 76
- August 22, 2024
FDA Approval of Alopecia Drug Positions Sun Pharma to Compete With Eli Lilly, Pfizer

Leqselvi is now FDA approved for treating severe alopecia areata. Sun Pharma added the oral drug to its pipeline via the $576 million acquisition of Concert Pharmaceuticals last year. By Frank Vinluan Hair loss caused by alopecia areata now has a new FDA-approved treatment, a third-in-class drug from Sun Pharmaceutical Industries that will compete against commercialized medicines from Eli Lilly and Pfizer. The regulatory decision announced Friday for the drug, deuruxolitinib, covers the treatment of adults with severe alopecia areata. Mumbai, India-based Sun Pharma, which has U.S. operations in Princeton, New Jersey, will market the twice-daily pill under the brand name Leqselvi. Alopecia areata is a condition in which the immune system attacks hair follicles, causing sudden hair loss. The disorder affects both males and females. While the hair loss mainly happens on the scalp, the condition can affect other parts of the body. Sun Pharma cites studies estimating that 700,000 ...
- Source: drugdu
- 126
- July 30, 2024
Eli Lilly Shows Appetite for Oral Immunology Drugs, Swallowing Morphic in $3.2B Deal

Eli Lilly’s Morphic acquisition brings an oral small molecule that blocks the same target as Entvyio, an injectable inflammatory bowel disease drug from Takeda Pharmaceutical. The Morphic deal follows Lilly’s 2023 acquisition of Dice Therapeutics, another company developing oral immunology medications. By Frank VinluanEli Lilly has immunology and inflammation products administered by injection, but the pharmaceutical giant is among the companies interested in bringing patients more convenient pill formulations. Its $3.2 billion acquisition of Morphic comes with a lead drug candidate that’s an oral small molecule in mid-stage development for inflammatory bowel disease. According to deal terms announced Monday, Lilly is paying $57 in cash for each share of Waltham, Massachusetts-based Morphic. That price represents a 79% premium to Morphic’s closing stock price on Friday. The deal, which has been approved by the boards of directors of both companies, is expected to close in the third quarter of this year. ...
- Source: drugdu
- 106
- July 10, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.